Category
Glp 1
4 articles
GLP-1 Medication Shortage in Australia: Policy Failures, Access Inequity, and the Path to Reform
Australia's GLP-1 receptor agonist shortage exposes deep structural failures in medicines policy. This analysis examines the supply crisis, access inequities, the compounding pharmacy debate, and six concrete reforms needed to ensure equitable access to life-changing obesity and diabetes treatments.
Bariatric Surgery Access in Australia: Policy Failures, Equity Gaps, and the Case for Reform
Australia's bariatric surgery system is two-tiered, inequitable, and failing hundreds of thousands of people with severe obesity. A policy analysis of access barriers, public waitlist failures, the economic case for expanded funding, and the role of GLP-1 medications in reshaping the surgical pipeline.
Medicare and PBS Reform for Obesity Treatment: What Australia Needs to Do
Australia's PBS coverage of obesity medications is inadequate, inequitable, and out of step with the clinical evidence. A policy analysis of the case for expanded PBS listing of GLP-1 receptor agonists and what reform should look like.
Metabolic Syndrome in Australia: The Policy Gap Between Evidence and Action
Australia's metabolic syndrome burden is large, growing, and poorly addressed by current Medicare and public health policy. An evidence-based analysis of the gap between what the research shows and what the health system delivers.